Transcriptomics

Dataset Information

0

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [HER2mouse resistant RNAseq]

ABSTRACT: We treated tumour-bearing MMTV-rtTA/tetO-HER2 female mice with 75 mg/kg Abemaciclib for ~4 weeks (or until point of resistance, where tumours have started to grow again). Mice were then divided into treatment groups, receiving vehicle (veh), INX-315 (INX), Abemaciclib (LY) or both INX-315 and Abema in combination (LY.INX). Resistant tumors were collected and RNA sequencing performed.

ORGANISM(S): Mus musculus

PROVIDER: GSE243148 | GEO | 2023/11/22

REPOSITORIES: GEO

Json Xml

Similar Datasets

Transcriptomics Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [HER2mouse upfront RNAseq]
2023-11-22 | GSE243149 | GEO
Genomics Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [MCF7 ATACseq]
2023-11-22 | GSE243147 | GEO
Transcriptomics Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OVCAR3 RNAseq]
2023-11-22 | GSE243152 | GEO
Transcriptomics Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OV5398PDX RNAseq]
2023-11-22 | GSE243151 | GEO
Transcriptomics Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [Gastric mouse (GA0103) RNAseq]
2023-11-22 | GSE243153 | GEO
Transcriptomics Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [MCF7 and T47D RNAseq]
2023-11-22 | GSE243150 | GEO
Genomics FiTAc-seq analysis of PDX 14-07 and MMTV-rtTA/tetO/Her2 tumors treated with abemaciclib
2020-09-03 | GSE157384 | GEO
Transcriptomics Transcriptomic analysis in murine mammary carcinoma tissue after treatment with control vehicle or abemaciclib
2017-08-17 | GSE99061 | GEO
Transcriptomics Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors
2023-11-22 | GSE243154 | GEO
Genomics FiT-seq analysis of PDX 14-07 and MMTV-rtTA/tetO/Her2 tumors treated with abemaciclib
| PRJNA548956 | ENA